このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Idorsia マネジメント

マネジメント基準チェック /34

Idorsia'sの CEO はJean-Paul Clozelで、 Jan2017年に任命され、の在任期間は 7.58年です。の年間総報酬はCHF 1.98Mで、 37.8%給与と62.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の19.91%を直接所有しており、その価値はCHF 75.66M 。経営陣と取締役会の平均在任期間はそれぞれ7.2年と3.3年です。

主要情報

Jean-Paul Clozel

最高経営責任者

CHF 2.0m

報酬総額

CEO給与比率	37.8%
CEO在任期間	7.8yrs
CEOの所有権	19.9%
経営陣の平均在職期間	7.3yrs
取締役会の平均在任期間	3.4yrs

経営陣の近況

Recent updates

Take Care Before Jumping Onto Idorsia Ltd (VTX:IDIA) Even Though It's 25% Cheaper

Sep 18

Idorsia Ltd (VTX:IDIA) Stock Rockets 26% But Many Are Still Ignoring The Company

May 30

Idorsia Ltd (VTX:IDIA) Analysts Are Reducing Their Forecasts For This Year

May 26

Idorsia Ltd (VTX:IDIA) Analysts Just Slashed Next Year's Revenue Estimates By 17%

May 01

Industry Analysts Just Made A Captivating Upgrade To Their Idorsia Ltd (VTX:IDIA) Revenue Forecasts

Apr 05

Need To Know: Analysts Are Much More Bullish On Idorsia Ltd (VTX:IDIA) Revenues

Mar 10

Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry

Mar 08

There's No Escaping Idorsia Ltd's (VTX:IDIA) Muted Revenues Despite A 37% Share Price Rise

Dec 28

CEO報酬分析

Idorsia の収益と比較して、Jean-Paul Clozel の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	CHF 29m
Mar 31 2024	n/a	n/a	-CHF 56m
Dec 31 2023	CHF 2m	CHF 750k	-CHF 298m
Sep 30 2023	n/a	n/a	-CHF 374m
Jun 30 2023	n/a	n/a	-CHF 814m
Mar 31 2023	n/a	n/a	-CHF 843m
Dec 31 2022	CHF 3m	CHF 750k	-CHF 828m
Sep 30 2022	n/a	n/a	-CHF 887m
Jun 30 2022	n/a	n/a	-CHF 810m
Mar 31 2022	n/a	n/a	-CHF 728m
Dec 31 2021	CHF 3m	CHF 750k	-CHF 635m
Sep 30 2021	n/a	n/a	-CHF 520m
Jun 30 2021	n/a	n/a	-CHF 499m
Mar 31 2021	n/a	n/a	-CHF 429m
Dec 31 2020	CHF 3m	CHF 750k	-CHF 445m

報酬と市場: Jean-Paulの総報酬 ($USD 2.32M ) は、 Swiss市場 ($USD 1.25M ) の同規模の企業の平均を上回っています。

報酬と収益: Jean-Paulの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jean-Paul Clozel (69 yo)

7.8yrs

在職期間

CHF 1,981,794

報酬

Mr. Jean-Paul Clozel, M.D., has been Chairman of the Board of Idorsia Ltd. since June 13, 2024 and serves as its Chief Executive Officer since 2017. He is Executive Director of Idorsia Ltd.He co-founded A...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jean-Paul Clozel	CEO & Chairman of the Board	7.8yrs	CHF 1.98m	19.91% CHF 50.8m
Andre Muller	Executive VP & CFO	7.8yrs	データなし	0.058% CHF 148.4k
Martine Clozel	Executive VP & Chief Scientific Officer	7.8yrs	データなし	7.1% CHF 18.1m
Guy Braunstein	Executive VP & Chief Medical Officer	no data	データなし	0.11% CHF 288.9k
Alberto Gimona	Executive VP & Head of Global Clinical Development	5.7yrs	データなし	0.0074% CHF 18.8k
Andrew Weiss	Senior VP and Head of Investor Relations & Corporate Communications	7.3yrs	データなし	データなし
Julien Gander	Senior VP	1.9yrs	データなし	データなし
Alexander Khatuntsev	Senior VP & Head of Global Human Resources	7.3yrs	データなし	データなし
Olivier Lambert	Senior VP & Head of Technical Operations	no data	データなし	データなし
Markus Riederer	Senior VP & Head of Drug Discovery Biology	no data	データなし	データなし
Christoph Boss	Senior VP & Head of Drug Discovery Chemistry	no data	データなし	データなし

7.3yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: IDIAの経営陣は経験豊富で経験豊富です（平均在職期間は7.2年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Jean-Paul Clozel	CEO & Chairman of the Board	less than a year	CHF 1.98m	19.91% CHF 50.8m
Peter Kellogg	Non-Executive Director	3.4yrs	CHF 149.37k	0.021% CHF 54.1k
Joern Aldag	Non-Executive Director	4.4yrs	CHF 156.82k	0.022% CHF 56.3k
Felix Ehrat	Non-Executive Director	4.4yrs	CHF 174.78k	0.056% CHF 144.1k
Bart Filius	Non-Executive Director	less than a year	データなし	データなし
Mathieu Simon	Vice-Chairman & Lead Independent Director	5.4yrs	CHF 344.19k	0.072% CHF 183.6k
Sophie Kornowski-Bonnet	Non-Executive Director	1.4yrs	CHF 117.54k	0.013% CHF 32.4k
Sandesh Mahatme	Non-Executive Director	4.4yrs	CHF 172.30k	0.026% CHF 66.7k
Srishti Gupta	Non-Executive Director	3.4yrs	CHF 161.88k	0.026% CHF 65.6k

3.4yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: IDIAの取締役会は経験豊富であると考えられます ( 3.3年の平均在任期間)。

Idorsia マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Idorsia Ltd Approves Board Appointments

No independent directors

No independent directors

Recent updates

Investor sentiment deteriorates as stock falls 15%

Take Care Before Jumping Onto Idorsia Ltd (VTX:IDIA) Even Though It's 25% Cheaper

Investor sentiment deteriorates as stock falls 18%

Investor sentiment deteriorates as stock falls 19%

Consensus EPS estimates upgraded to CHF0.91 loss

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Idorsia Ltd to Report Fiscal Year 2024 Results on Feb 27, 2025

Idorsia Ltd Receives Approval from the European Commission for JERAYGO™

Idorsia Ltd Approves Board Appointments

Consensus revenue estimates fall by 16%

Idorsia Ltd (VTX:IDIA) Stock Rockets 26% But Many Are Still Ignoring The Company

Consensus revenue estimates fall by 44%

Idorsia Ltd (VTX:IDIA) Analysts Are Reducing Their Forecasts For This Year

Full year 2023 earnings released: CHF1.67 loss per share (vs CHF4.67 loss in FY 2022)

Idorsia Ltd to Report Nine Months, 2024 Results on Oct 29, 2024

Idorsia Ltd (VTX:IDIA) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Industry Analysts Just Made A Captivating Upgrade To Their Idorsia Ltd (VTX:IDIA) Revenue Forecasts

Price target decreased by 17% to CHF1.72

Need To Know: Analysts Are Much More Bullish On Idorsia Ltd (VTX:IDIA) Revenues

Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry

There's No Escaping Idorsia Ltd's (VTX:IDIA) Muted Revenues Despite A 37% Share Price Rise

Consensus estimates of losses per share improve by 14%

Idorsia Ltd Announces New Phase 3 Data with Aprocitentan for Patients with Resistant Hypertension Presents At the American Society of Nephrology Kidney Week 2023

Price target decreased by 11% to CHF4.79

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Idorsia Ltd Updates Earnings Guidance for the Year 2023

Price target decreased by 9.9% to CHF5.91

Price target decreased by 8.6% to CHF9.36

The Idorsia Ltd (VTX:IDIA) Analysts Have Been Trimming Their Sales Forecasts

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus estimates of losses per share improve by 11%

Idorsia Ltd to Report Q1, 2024 Results on Apr 25, 2024

Sosei Group Corporation (TSE:4565) entered into an agreement to acquire Idorsia Pharmaceuticals Japan Ltd/Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd (SWX:IDIA) for JPY 65 billion.

Price target decreased by 12% to CHF10.24

New major risk - Share price stability

Idorsia Ltd's (VTX:IDIA) P/S Still Appears To Be Reasonable

Idorsia Launches Quviviq (Daridorexant) in Switzerland – A First-In-Class Treatment for Chronic Insomnia Disorder to Improve Both Nighttime Symptoms and Daytime Functioning

Price target decreased by 14% to CHF11.60

Price target decreased by 9.9% to CHF13.72

Price target decreased by 12% to CHF13.46

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 12% to CHF13.46

Consensus EPS estimates fall by 14%

Price target decreased by 7.8% to CHF15.45

Price target decreased by 7.6% to CHF16.29

Idorsia Ltd Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Idorsia Ltd Provides Earnings Guidance for the Year 2023

No longer forecast to breakeven

Idorsia Ltd to Report Q3, 2023 Results on Oct 24, 2023

Forecast to breakeven in 2025

Idorsia Ltd Submits New Drug Application to the US FDA for Aprocitentan for Treatment of Patients with Difficult-to-Control Hypertension

Price target decreased to CHF18.17

Idorsia Ltd Announces Long-Term Safety and Tolerability Results with Daridorexant in Patients with Insomnia Disorder Published in CNS Drugs

Idorsia Ltd Announces Swissmedic Approves QUVIVIQ (daridorexant) – A First-In-Class Treatment for Chronic Insomnia Disorder to Improve Both Nighttime Symptoms and Daytime Functioning

No independent directors

The Janssen Pharmaceutical Companies, in Collaboration with Idorsia Ltd, Announce Results from the Phase 3 Precision Study

The Janssen Pharmaceutical Companies, in Collaboration with Idorsia Ltd, Announce Results from the Phase 3 Precision Study

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Consensus forecasts updated

Idorsia Ltd Provides Earnings Guidance for the Year 2022

Price target decreased to CHF23.41

Now 21% undervalued after recent price drop

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Idorsia Ltd to Report Q1, 2023 Results on Apr 25, 2023

Now 22% undervalued after recent price drop

Idorsia Ltd Announces Positive Phase 3 Study with Aprocitentan Demonstrates Significant Antihypertensive Efficacy in Patients with Resistant Hypertension

Idorsia Ltd Announces Phase 2A Study Results in Binge Eating Disorder

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

No independent directors

マネジメント基準チェック /34